Boston, MA, US – Zipcode Bio, a startup focusing on next-generation nucleic acid applications, congratulates Co-Founder, Dr. Drew Weissman on receiving the 2023 Nobel Prize in Physiology or Medicine at the Nobel Prize Ceremony in Stockholm, Sweden. The company applauds Dr. Weissman for his exceptional contributions to mRNA technology.
Dr. Weissman has played a crucial role in shaping the company’s mission to develop innovative and cost-effective treatments. Leveraging precise genetic instructions, Zipcode Bio focuses on advancing targeted delivery solutions for nucleic acids, including mRNA and oligonucleotides, ensuring optimal therapeutic outcomes and tolerability.
“We are immensely proud of Dr. Drew Weissman for his well-deserved recognition with the 2023 Nobel Prize, acknowledging his pioneering contributions to mRNA technology. His vision and leadership have been pivotal in advancing next-generation nucleic acid applications with targeted delivery,” said Dr. Jason Zhang, Co-Founder and CEO at Zipcode Bio.
About Zipcode Bio: Zipcode Bio is a biotechnology company specializing in the development of next-generation nucleic acid applications. It is co-Founded by Dr. Drew Weissman, Dr. Virgil Percec and Dr. Jason Zhang in Nov. 2023. The scientific strength is based on the co-founders’ breakthrough DNP technology. Zipcode Bio stands at the forefront of developing revolutionary solutions with the potential to transform patient care. Zipcode Bio has assembled a dynamic team committed to pushing scientific boundaries and developing novel therapeutics to address unmet healthcare needs. The company’s dedication to innovation, precision, and accessibility underscores its mission to improve therapeutic outcomes and contribute to the evolution of global healthcare.
For more information, please contact firstname.lastname@example.org